Loading...
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
BACKGROUND: Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor receptor alpha, RET, and KIT. This phase 2, single-arm, open-label multicenter study evaluated lenvatinib in advanced hepatocellular c...
Na minha lista:
| Udgivet i: | J Gastroenterol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Japan
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5357473/ https://ncbi.nlm.nih.gov/pubmed/27704266 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-016-1263-4 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|